替吉奥单药治疗老年或体弱转移性结直肠癌患者疗效分析被引量：3

Efficacy of S-1 Monotherapy in the Treatment of Elderly or Frail Patients with Metastatic Colorectal Cancer

下载PDF

导出

摘要目的观察分析替吉奥单药作为老年或体弱转移性结直肠癌（m CRC）患者治疗方案的疗效和毒副反应。方法 24例老年或体弱m CRC患者接受口服替吉奥治疗,即替吉奥35 mg·m-2,每天2次,连用2周,停药1周。观察其近期疗效、疾病无进展生存期、总生存期、毒副反应等。结果全组24例患者的总有效率为16.7%,疾病控制率为75.0%;中位无进展生存期为4.1（95%CI为2.8~5.4）个月,中位总生存期：12.3（95%CI为9.9~14.7）个月;主要毒副反应为胃肠道反应、骨髓抑制,多为轻度,无患者因毒副反应终止治疗。结论替吉奥单药治疗老年或体弱m CRC患者安全性高、疗效好。 Objective To evaluate the efficacy and toxicities of S-1 monotherapy in the treatment of elderly or frail patients with metastatic colorectal cancer. Methods A total of 24 elderly or frail patients with metastatic colorectal cancer were eligible for S-1 of 35 mg·m- 2given twice daily for 2 weeks followed by 1 week of rest. The shortterm effects,progression-free survival,overall survival time,toxicities were observed. Results The overall response rate of all the 24 patients was 16. 7%,the disease control rate was 75. 0%. The median progression-free survival was4. 1 months（ 95% CI 2. 8-5. 4 months）,the median overall survival was 12. 3 months（ 95% CI 9. 9-14. 7months）. The main toxicities were gastrointestinal reactions and bone marrow suppression,none of the patients terminated treatment due to toxicities. Conclusion S-1 monotherapy was well-tolerated and efficacious in the treatment of elderly or frail patients with metastatic colorectal cancer.

作者孟秋丽吴晓邡

机构地区巩义市人民医院肿瘤血液科

出处《肿瘤基础与临床》 2016年第1期39-42,共4页 journal of basic and clinical oncology

关键词替吉奥老年患者体弱患者转移性结直肠癌 S-1 elderly patients frail patients metastatic colorectal cancer

分类号 R735.3 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献18

1Yancik R, Ries LA. Cancer in older persons : an international issue in an aging world [ J ]. Semin Oncol, 2004,31 ( 2 ) : 128 - 136.
2Go[dberg RM. Therapy for metastatic colorectal cancer[ J ]. Oncolo- gist, 2006,11 (9) :981 - 987.
3Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for 'the management of metastatic colorectal cancer [ J ]. Oncologist, 2007,12 ( 1 ) : 38 - 50.
4Ledermann JA, Leonard P, Seymour M. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer [J]. N Engl J Med, 2001,345(2) :145 - 146.
5赖灿辉,张江灵,郑维斌,陈云萍.替吉奥维持治疗晚期结直肠癌的临床疗效[J].中国肿瘤临床与康复,2015,22(2):194-196. 被引量：7
6李陆,王蓉,何怡.单药替吉奥一线治疗老年晚期结直肠癌临床疗效观察[J].西南军医,2015,17(1):22-24. 被引量：2
7Shin SJ,Jeong JH,Park YS,et al. Phase Ⅱ trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer[ J]. In- vest New Drugs, 2011,29 (5):1073 -1080.
8Yasui H, Muro K, Shimada Y, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal canc- er: updated results of the FIRIS study[ J]. J Cancer Res Clin On- col, 2015,141(1) :153 - 160.
9Shingai T, Sakai D, Sugimoto N, et al. A feasibility study of adju- vant therapy with eapecitabine plus oxaliplatin (XELOX) for Japa- nese patients with advanced colorectal cancer[ J]. Gan To Kagaku Ryoho, 2015,42(2) :195 - 199.
10Koopman M, Antonini NF, Douma J, et al. Sequential versus combi- nation chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO) : a phase Ⅲ randomised controlled trial [ J ]. Lancet, 2007,370 (9582) : 135 - 142.

二级参考文献15

1秦叔逵,马军.中国临床肿瘤学进展[M].北京:人民卫生出版社,2011:92.
2Meng Y,Yang JW.Maintenance treatment of metastatic colorectal cancer[J].Int J Pathol Clin Med,2013,33:412-415.
3Goldie JH,Coldman AJ.A mathematical model for relating the drug sensitivity of tumors to theirs spontaneous mutation rate[J].Cancer Treat Rep,1979,63:1727-1733.
4Day RS.Treatment sequencing,asymmetry,and uncertainty:protocol strategies for combination chemotherapy[J].Cancer Res,1986,46:3876-3885.
5Waddell T,Gollins S,Soe W,et al.Phase II study of shortcourse capecitabine plus oxaliplatin(XELOX)followed by maintenance capecitabine in advanced colorectal cancer:Xel Quali study[J].SCancer Chemother Pharmacol,2011,67:1111-1117.
6Nakayama G,Kodera Y,Yokoyama H,et al.Modified FOLFOX6with oxaliplatin stop-and-go stategy and oral S-1 maintennance therapy in advanced colorectal cancer:CCOG-0704 study[J].Int J Clin Oncol,2011,16:506-511.
7潘宏铭,许农.肿瘤内科疾病临床治疗与合理川药[M].北京:科学技术文献出版社,2007:356.
8Sch6ffski P. The modulated oral feuoropyrimidine prodrug s-1, and its use in gastrointestinal cancer and other solid tu- mors [ J ]. Anticancer Drugs,2004, 15 (2) : 85-106.
9Tanaka F, Fukuse T, wada H, etal. The history mechanism and dinical use of oral s-fluorouracil derivative chemothera- peutis agents[J]. Curt Pharm Biotechnol, 2000,1 (2): 137-164.
10A Ohtsu,H Baba,Y Sakata,et al, Phase 1I study of S-l,a nov- el oral fluoropyrimidine derivative,in patients with meta- static colorectal carcinoma[J].British Journal of Cancer, 2000,83(2):141-145.